Kathleen S. Capps
Known title: See RemarksCIK: 0002085127
Associated companies
Transaction History
| ENTA | ▼ Sell | Open Market | 323 | $5K | 12/5/2025 | View on chart |
| ENTA | ▼ Sell | Open Market | 207 | $3K | 12/2/2025 | View on chart |
| ENTA | ▼ Sell | Tax Withholding | 85 | $1K | 12/1/2025 | View on chart |
| ENTA | ▲ Buy | Grant | 3,163 | $0 | 11/25/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
HC Wainwright Maintains $20 Target for Enanta
HC Wainwright reiterated its stance on Enanta Pharmaceuticals, keeping a price target of $20. This view aligns with the broader analyst consensus, where the average target across six analysts is $21.83. The stock is currently trading near its 52-week low, with recent technical signals indicating support at $13.25.
HC Wainwright Maintains $20 Target for Enanta. HC Wainwright reiterated its stance on Enanta Pharmaceuticals, keeping a price target of $20. This view aligns with the broader analyst consensus, where the average target across six analysts is $21.83. The stock is currently trading near its 52-week low, with recent technical signals indicating support at $13.25.